期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

前列腺癌生物标记物的研究进展 被引量：6

下载PDF
导出
摘要 前列腺癌是男性常见恶性肿瘤，其发病率和死亡率分别位居全球男性全部恶性肿瘤的第2位和第6位。我国Pca的发病率很低，但近年来，但随着人均寿命的延长、膳食结构的改变以及诊断技术的提高，其发病率也逐年增加。目前前列腺癌诊断的基本方法中，血清前列腺特异性抗原（Pros-tate specific antigen，PSA）是筛选Pca最重要的参考指标，然而，其指导Pca早期诊断的敏感性和特异性并不理想。
作者 吴禹铮 郑素琴
机构地区 河北联合大学基础医学院病理教研室
出处 《淮海医药》 CAS 2014年第6期F0003-F0004,共2页 Journal of Huaihai Medicine
关键词 前列腺肿瘤 生物标记物 检测 研究进展
分类号 R365 [医药卫生—病理学] R737.25 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J ]. CA cancer J clin,2011,6(2) :69-90.
  • 2韩苏军,张思维,陈万青,李长岭.中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志,2013,18(4):330-334. 被引量：769
  • 3孙颖浩.我国前列腺癌的研究现状[J].中华泌尿外科杂志,2004,25(2):77-80. 被引量：355
  • 4Thormpson IM, Pauler DK, Goodmans PJ, et al. preralenee of prostate cancer among men with a prostates pecific antigen level < or = 4. 0ng permilliter [ J ]. N Engl Jmed,2004,350 (22) :2239-2246.
  • 5Jiang Z, Li C, Fischer A, et al. Using an AMACR (P504s)/ 34bateE12/P63 cocktail for the detection of small focasl prostate car- cinoma in needle biopsy specimens [ J ]. Am J clin patho1,2005,123 (2) :231-236.
  • 6Tosoian J, Loeb S. PSA and beyond : the past, present, and future of investigative biomarkers for prostate cancer[ J ]. The seientific world journal,2010,10 : 1919-1931.
  • 7Stamey TA, John stone IM, Me Neal JE, et al. preoperative serum prostate specific antigen levels between 2 and 22 ng/ml, correlate poorly with postradical prostateetomy cancer morphology, prostate specific antigen cure rates appear constant between 2 and 9 ng/ml [J]. J UROL,2002,167( 1 ) :103-111.
  • 8Okada Y,Osada M,Kurata S,et al. P53 gene family P51 (P63) -en- coded, secondary transaltivator 1'51B ( TAP63alpha ) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxic stress by accumulation [ J ]. Exp cell Res,2002,276 (2) : 194-200.
  • 9Grow AM, Vogcl AM, Monocloral antibody to human intermediate fil- ament proteins II Distribution of filament proteins in normal human tissues[J]. Am J Pathol,2010,114(2) :309-321.
  • 10姚世杰,史启铎,畅继武,张新,张淑敏,马洪顺.肿瘤标记物P504s在前列腺癌中的表达及应用价值[J].现代泌尿外科杂志,2007,12(3):170-172. 被引量：5

二级参考文献9

  • 1Rubin MA,Zhou M,Dhanasekaran SM,et al.Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer[J].JAMA,2002,287(13):1662-1670.
  • 2Kuefer R,Varambally S,Zhou M,et al.Alpha-methylacyl-CoA racemase:expression levels of this novel cancer biomarker depend on tumor differentiation[J].Am J Pathol,2002,161(3):841-848.
  • 3Zha S,Ferdinandusse S,Denis S,et al.Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer[J].Cancer Res,2003,63(21):7365-7376.
  • 4Yang XJ,Wu CL,Woda BA,et al.Expression of alpha-methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate[J].Am J Surg Pathol,2002,26(7):921-925.
  • 5赫杰,赵平,陈万青.2011中国肿瘤登记年报[M].北京:军事医学科学出版社,2012:2-5,26 -37,74 -75.
  • 6Segi M. Cancer mortality for selected sites in 24 countries(1950-57 ) [ M ]. Japan : Department of Public Health,Tohoku Univer-sity of Medicine, 1960.
  • 7FerlayJ, Shin HR, Bray F, et al. Estimates of worldwide burdenof cancer in 2008 : GLOBOCAN 2008 [ J]. Int J Cancer, 2010,127(12) : 2893 -2917.
  • 8Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin’2011,61(2) :69 -90.
  • 9Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [ J].CA Cancer J Clin,2012,62( 1) :10 - 29.

共引文献1117

同被引文献49

  • 1DAN-HUI LIU,XIAO-MIN WANG,LI-JUAN ZHANG,SONG-WEI DAI,LI-YUN LIU,JI-FU LIU,SHAN-SHAN WU,SHUAN-YING YANG,SAM FU,XUE-YUAN XIAO,DA-CHENG HE.Serum Amyloid A Protein: A Potential Biomarker Correlated With Clinical Stage of Lung Cancer[J].Biomedical and Environmental Sciences,2007,20(1):33-40. 被引量：12
  • 2Aoun F, Peltier A, van-Velthoven R. A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer[J]. Biomed Res Int, 2014, 2014: 501213. DOI:10.1155/2014/501213.
  • 3Heidenreich A, Bastian P J, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013[J]. Eur Urol, 2014, 65(1): 124-137. DOI:10.1016/j.eururo.2013.09.046.
  • 4Zacho H D, Manresa J A, Mortensen J C, et al. Observer agreement and accuracy in the evaluation of bone scans in newly diagnosed prostate cancer[J]. Nucl Med Commun, 2015, 36(5): 445-451. DOI:10.1097/MNM.0000000000000279.
  • 5Lara P N Jr, Ely B, Quinn D I, et al. Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421 [J]. J Natl Cancer Inst, 2014, 106(4): dju013. DOI:10.1093/jnci/dju013.
  • 6Kamiya N, Suzuki H, Endo T, et al. Clinical usefulness of bone markers in prostate cancer with bone metastasis[J]. Int J Urol, 2012, 19(11): 968-979. DOI:10.1111/j.1442-2042.2012.03098.x.
  • 7Zafeirakis A. Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer[J]. Hippokratia, 2010, 14(3): 164-169.
  • 8黄洪欣,辛志峰,姜长青,等.P504S、P63、CK34βE12、PSA 联合检测在前列腺良恶性病变中的表达及应用价值.中外健康文摘,2013,10(2):45-47.
  • 9陆鸿海,李爱华,钱小强,刘思宽.血清PSA与前列腺癌骨转移的关系[J].临床泌尿外科杂志,2008,23(4):263-265. 被引量：6
  • 10刘兴明,林丁,刘预,吴立翔,田明,林一民,黄学梅,易琳,杨静梅,张达容.羊Ⅰ型前胶原的提取、纯化与抗血清的制备应用于放免法的建立[J].重庆医学,2008,37(11):1203-1204. 被引量：1

引证文献6

二级引证文献21

淮海医药
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部